Prothena | PRTA - Operating Profit


Prothena reported $25.79M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Exelixis USD 248.41M 2.93M Jun/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD 700.4M 376.22M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Prothena USD 25.79M 53M Mar/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026